LATEST PRICE
$209.94
H 210.82 · L 208.55
Vol 265K · May 18
COMPOSITE SCORE
53.3
out of 100
RECOMMENDATION
WATCH
CONFIDENCE
71%
MODULES RUN
8/8
May 18, 14:13 UTC
Top Signals
- • CEO assessment: Strong leadership with successful product launches and strategic acquisitions.
- • Insider ownership: Moderate
- • CEO has over 6 years of tenure with a solid track record.
- • Consistent capital allocation towards R&D and shareholder returns.
- • No major governance scandals reported.
Price History
showing 7 of 30 days
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| May 18, 2026 | $210.37 | 210.82 | 208.55 | $209.94 | -0.45 (-0.2%) | 265K |
| May 15, 2026 | $213.10 | 214.92 | 209.02 | $210.39 | -0.38 (-0.2%) | 5.4M |
| May 14, 2026 | $209.50 | 213.51 | 208.35 | $210.77 | +2.27 (+1.1%) | 5.0M |
| May 13, 2026 | $206.86 | 209.53 | 204.30 | $208.50 | +0.64 (+0.3%) | 5.7M |
| May 12, 2026 | $204.59 | 211.32 | 203.51 | $207.86 | +5.08 (+2.5%) | 7.0M |
| May 11, 2026 | $202.01 | 205.38 | 202.01 | $202.78 | +1.23 (+0.6%) | 4.9M |
| May 08, 2026 | $201.92 | 202.40 | 200.02 | $201.55 | -1.16 (-0.6%) | 4.9M |
Module Breakdown — May 18, 14:13 UTC
| Module | Score | Confidence | Signals |
|---|---|---|---|
| Leadership |
85.0 |
65% | • CEO assessment: Strong leadership with successful product launches and strategic acquisitions. • Insider ownership: Moderate • CEO has over 6 years of tenure with a solid track record. • Consistent capital allocation towards R&D and shareholder returns. • No major governance scandals reported. • Strong alignment of compensation with long-term performance. |
| Moat |
75.0 |
65% | • Switching costs: High | Network effects: Moderate • Brand strength: High | Market position: Strong • Strong portfolio of patent-protected drugs • Established brand reputation • High barriers to entry in biopharma • Innovative R&D pipeline |
| FinancialHealth |
58.0 |
85% | • Profitable: Net income $695M • Slight revenue decline QoQ: -0.5% • Positive free cash flow: $3564M • Very high leverage: Debt/EBITDA 16.2x |
| Institutional |
50.0 |
40% | • No insider transactions found in last 90 days (SEC EDGAR Form 4) |
| Macro |
50.0 |
15% | • Sector performance data unavailable |
| Valuation |
50.0 |
78% | • P/E ratio unavailable (negative earnings) |
| Momentum |
43.0 |
95% | • Death cross: MA50 (209.35) < MA200 (218.89) • RSI elevated: 66.7 • MACD bullish crossover: 1.5398 > signal 0.5305 • Positive 20-day momentum: +2.3% |
| Sentiment |
30.0 |
15% | • Analysed 2 articles over 7 days (1 sentiment-scored) • Average sentiment: -0.50 — Positive: 0, Neutral: 0, Negative: 1 • Most bearish: "A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried?" (score -+0.50) |
Score History
showing 7 of 30 runs
| Date (UTC) | Score | Recommendation | Confidence | Modules |
|---|---|---|---|---|
| May 18, 14:13 | 53.3 | WATCH | 71% | 8 |
| May 17, 09:11 | 53.4 | WATCH | 71% | 8 |
| May 16, 12:21 | 53.5 | WATCH | 71% | 8 |
| May 15, 11:11 | 53.3 | WATCH | 71% | 8 |
| May 14, 10:05 | 52.2 | WATCH | 71% | 8 |
| May 13, 09:12 | 53.1 | WATCH | 71% | 8 |
| May 12, 09:40 | 53.1 | WATCH | 71% | 8 |